Abstract:The last decade saw impressive advances not only in the discovery of gene mutations causing epilepsy, but also in unraveling the molecular mechanisms underlying the clinical manifestations of the disease. Increasing evidence is emerging that understanding these mechanisms is relevant for selection of the most appropriate treatment in the affected individual(s). The present article discusses the therapeutic implications of epilepsy-causing variants affecting a broad range of targets, from ion channels to genes controlling cellular metabolism and cell signaling pathways. Identification of a precise genetic etiology can direct physicians to (i) prescribe treatments that correct specific metabolic defects (e.g., the ketogenic diet for GLUT1 deficiency, or pyridoxine for pyridoxine-dependent epilepsies); (ii) avoid antiepileptic drugs (AEDs) that can aggravate the pathogenic defect (e.g., sodium channel blocking drugs in SCN1A-related Dravet syndrome), or (iii) select AEDs that counteract the functional disturbance caused by the gene mutation (e.g., sodium channel blockers for epilepsies due to gain-of-function SCN8A mutations). In some instances, different pathogenic variants of the same gene can have opposite functional effects, which determines whether certain treatments can be beneficial or deleterious (e.g., gain-of-function versus loss-of-function variants in SCN2A determine whether sodium channel blockers improve or worsen seizure control). There are also cases where functional disturbances caused by the gene defect may not be corrected by existing AEDs, but can be countered by medications already available in the market for other indications (e.g., memantine has been used to treat the epileptic encephalopathy caused by a specific gain-of-function GRIN2A mutation), thus making 'drug repurposing' a valuable tool for personalized epilepsy therapies. As our understanding of pathogenic mechanisms improve, opportunities arise for development of treatments targeting the specific gene defect or its consequences. Everolimus, an mTOR inhibitor approved for the treatment of focal seizures associated with tuberous sclerosis complex, is an example of a medication targeting the etiological mechanisms of the disease. Several treatments aimed at correcting specific pathogenic defects responsible for rare genetic epilepsies are currently in development, and range from traditional small molecules to novel approaches involving peptides, antisense oligonucleotides, and gene therapy.

Genetic Background of Epilepsy and Antiepileptic Treatments

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

GABAA receptor epilepsy mutations

Identifying mutations in epilepsy genes: Impact on treatment selection

Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment

The Molecular Biology of Genetic-Based Epilepsies

Recent Progress in Identifying Genetic and Epigenetic Contributions to Epilepsy

Voltage-gated potassium channels and genetic epilepsy

Advances in the studies on the molecular and genetic aspects of epilepsy]

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy

Gene Variations of Glutamate Metabolism Pathway and Epilepsy

New avenues in molecular genetics for the diagnosis and application of therapeutics to the epilepsies

Genetic and epigenetic mechanisms of epilepsy: a review

Preface: Special issue: "Ion channels and genetic epilepsy"

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

Genetic Forms of Epilepsies and Other Paroxysmal Disorders

Individualized Medicine for Epilepsy -Based on Genetic Information-

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies

[Experience in the management of patients with genetic epilepsies and epileptic encephalopathies in the outpatient practice]